Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of "Hold" by Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have earned an average rating of "Hold" from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $7.31.

Several equities research analysts recently commented on the company. The Goldman Sachs Group lowered Maravai LifeSciences from a "neutral" rating to a "sell" rating and cut their target price for the company from $7.00 to $4.25 in a research report on Thursday, December 5th. UBS Group cut their price target on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a report on Friday, March 21st. Morgan Stanley lowered their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a research note on Tuesday, March 25th. Baird R W downgraded shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Finally, Guggenheim began coverage on shares of Maravai LifeSciences in a report on Thursday, December 19th. They issued a "neutral" rating for the company.

Maravai LifeSciences Trading Up 0.4 %

MRVI stock traded up $0.01 during midday trading on Thursday, hitting $2.36. The stock had a trading volume of 2,820,403 shares, compared to its average volume of 2,325,960. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The firm has a market cap of $600.23 million, a P/E ratio of -1.44 and a beta of -0.08. The business has a fifty day moving average price of $3.73 and a two-hundred day moving average price of $5.56. Maravai LifeSciences has a 1-year low of $2.07 and a 1-year high of $11.56.

Remove Ads

Insider Activity

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the sale, the general counsel now owns 167,618 shares in the company, valued at $843,118.54. This represents a 12.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.63% of the company's stock.

Institutional Trading of Maravai LifeSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRVI. Performa Ltd US LLC boosted its position in shares of Maravai LifeSciences by 614.3% during the fourth quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock valued at $27,000 after buying an additional 4,300 shares during the last quarter. FNY Investment Advisers LLC lifted its stake in Maravai LifeSciences by 600.0% during the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company's stock valued at $38,000 after acquiring an additional 6,000 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Maravai LifeSciences by 3,541.4% during the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company's stock valued at $56,000 after acquiring an additional 9,916 shares in the last quarter. Cibc World Markets Corp purchased a new position in Maravai LifeSciences during the 4th quarter worth $56,000. Finally, Atria Investments Inc bought a new stake in shares of Maravai LifeSciences in the 4th quarter worth $58,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.